Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:XYZ_Biotech
|
| gptkbp:ceo |
gptkb:Peter_Weyland
|
| gptkbp:clinical_trial |
Multiple ongoing
|
| gptkbp:employees |
500+
|
| gptkbp:founded |
gptkb:2010
|
| gptkbp:founder |
gptkb:Peter_Weyland
|
| gptkbp:headquarters |
gptkb:Los_Angeles,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Weyland Pharmaceuticals
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:investment |
R& D
|
| gptkbp:mission |
Innovate healthcare solutions
|
| gptkbp:partnerships |
Various biotech firms
|
| gptkbp:products |
Biopharmaceuticals
|
| gptkbp:research_focus |
Genetic Engineering
|
| gptkbp:revenue |
$1 billion (2022)
|
| gptkbp:website |
www.weylandpharma.com
|
| gptkbp:bfsParent |
gptkb:Weyland_Corporation
gptkb:Weyland_Industries |
| gptkbp:bfsLayer |
5
|